Pfizer (NYSE:PFE) Releases Earnings Results, Beats Expectations By $0.20 EPS

Key Points

• Pfizer reported quarterly earnings of $0.78 EPS, surpassing analyst expectations of $0.57 EPS by $0.21, along with a revenue of $14.65 billion, which is above the predicted $13.43 billion.
• The company declared a quarterly dividend of $0.43 per share, yielding approximately 7.0%, with a payout ratio of 124.64%.
• Pfizer's stock price increased to $24.42 following the earnings report, while analysts maintain a Moderate Buy consensus rating with an average target price of $28.28.

Pfizer (NYSE:PFE - Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20, Zacks reports. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. Pfizer updated its FY 2025 guidance to 2.900-3.100 EPS.

Pfizer Stock Up 4.9%

Shares of NYSE:PFE opened at $24.69 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a market cap of $140.37 billion, a P/E ratio of 17.89, a P/E/G ratio of 0.85 and a beta of 0.52. The company's 50-day moving average price is $24.39 and its two-hundred day moving average price is $24.54.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio is currently 124.64%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pfizer stock. Brighton Jones LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1,282.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 666,318 shares of the biopharmaceutical company's stock after acquiring an additional 618,117 shares during the period. Brighton Jones LLC's holdings in Pfizer were worth $17,677,000 at the end of the most recent quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PFE shares. TD Cowen cut their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. BMO Capital Markets cut their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Bank of America increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Morgan Stanley increased their price objective on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.